94 related articles for article (PubMed ID: 17332347)
1. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
Gallmeier E; Hucl T; Brody JR; Dezentje DA; Tahir K; Kasparkova J; Brabec V; Bachman KE; Kern SE
Cancer Res; 2007 Mar; 67(5):2169-77. PubMed ID: 17332347
[TBL] [Abstract][Full Text] [Related]
2. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.
Palagyi A; Neveling K; Plinninger U; Ziesch A; Targosz BS; Denk GU; Ochs S; Rizzani A; Meier D; Thasler WE; Hanenberg H; De Toni EN; Bassermann F; Schäfer C; Göke B; Schindler D; Gallmeier E
Mol Cancer; 2010 May; 9():127. PubMed ID: 20509860
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.
Martínez S; Pérez L; Galmarini CM; Aracil M; Tercero JC; Gago F; Albella B; Bueren JA
Br J Pharmacol; 2013 Oct; 170(4):871-82. PubMed ID: 23937566
[TBL] [Abstract][Full Text] [Related]
4. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway.
Landais I; Sobeck A; Stone S; LaChapelle A; Hoatlin ME
Int J Cancer; 2009 Feb; 124(4):783-92. PubMed ID: 19048618
[TBL] [Abstract][Full Text] [Related]
5. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
[TBL] [Abstract][Full Text] [Related]
6. DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.
Shukla P; Solanki A; Ghosh K; Vundinti BR
Eur J Haematol; 2013 Nov; 91(5):381-93. PubMed ID: 23859405
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents.
Kee Y; Huang M; Chang S; Moreau LA; Park E; Smith PG; D'Andrea AD
Mol Cancer Res; 2012 Mar; 10(3):369-77. PubMed ID: 22219386
[TBL] [Abstract][Full Text] [Related]
8. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.
Gallmeier E; Kern SE
Clin Cancer Res; 2007 Jan; 13(1):4-10. PubMed ID: 17200332
[TBL] [Abstract][Full Text] [Related]
9. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability.
Bogliolo M; Lyakhovich A; Callén E; Castellà M; Cappelli E; Ramírez MJ; Creus A; Marcos R; Kalb R; Neveling K; Schindler D; Surrallés J
EMBO J; 2007 Mar; 26(5):1340-51. PubMed ID: 17304220
[TBL] [Abstract][Full Text] [Related]
10. DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway.
Bhattacharjee S; Nandi S
Cell Commun Signal; 2017 Oct; 15(1):41. PubMed ID: 29017571
[TBL] [Abstract][Full Text] [Related]
11. The Fanconi anemia pathway and ICL repair: implications for cancer therapy.
Wang LC; Gautier J
Crit Rev Biochem Mol Biol; 2010 Oct; 45(5):424-39. PubMed ID: 20807115
[TBL] [Abstract][Full Text] [Related]
12. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
Kennedy RD; Chen CC; Stuckert P; Archila EM; De la Vega MA; Moreau LA; Shimamura A; D'Andrea AD
J Clin Invest; 2007 May; 117(5):1440-9. PubMed ID: 17431503
[TBL] [Abstract][Full Text] [Related]
13. Fanconi anemia pathway--the way of DNA interstrand cross-link repair.
Yao CJ; Du W; Zhang Q; Zhang F; Zeng F; Chen FP
Pharmazie; 2013 Jan; 68(1):5-11. PubMed ID: 23444773
[TBL] [Abstract][Full Text] [Related]
14. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis.
De Toni EN; Ziesch A; Rizzani A; Török HP; Hocke S; Lü S; Wang SC; Hucl T; Göke B; Bruns C; Gallmeier E
Oncotarget; 2016 Feb; 7(8):9477-90. PubMed ID: 26843614
[TBL] [Abstract][Full Text] [Related]
16. C. elegans: a model of Fanconi anemia and ICL repair.
Youds JL; Barber LJ; Boulton SJ
Mutat Res; 2009 Jul; 668(1-2):103-16. PubMed ID: 19059419
[TBL] [Abstract][Full Text] [Related]
17. Impaired removal of DNA interstrand cross-link in Nijmegen breakage syndrome and Fanconi anemia, but not in BRCA-defective group.
Tsuchida K; Komatsu K
Cancer Sci; 2008 Nov; 99(11):2238-43. PubMed ID: 18771529
[TBL] [Abstract][Full Text] [Related]
18. The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.
Akkari YM; Bateman RL; Reifsteck CA; D'Andrea AD; Olson SB; Grompe M
Mol Genet Metab; 2001 Dec; 74(4):403-12. PubMed ID: 11749045
[TBL] [Abstract][Full Text] [Related]
19. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
20. BLM promotes the activation of Fanconi Anemia signaling pathway.
Panneerselvam J; Wang H; Zhang J; Che R; Yu H; Fei P
Oncotarget; 2016 May; 7(22):32351-61. PubMed ID: 27083049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
